Akums Drugs & Pharmaceuticals Ltd. (AKUMS.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-35.7%

₹475.37

vs ₹739.70 price

Levered DCF

₹1,491.31

After debt service

Piotroski score

—

Altman Z-score

—

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
P/E	27.96×	20.92×	-2,843.75×	132.05×	-49.64×
P/B	2.15×	2.32×	16.17×	17.47×	20.15×
P/S	1.64×	1.74×	2.85×	3.61×	3.44×
EV / EBITDA	10.95×	13.34×	91.33×	42.38×	-156.64×
Gross margin	21.5%	39.4%	35.8%	33.6%	34.8%
Operating margin	8.4%	7.6%	9.0%	5.5%	8.8%
Net margin	5.9%	8.3%	-0.1%	2.7%	-6.9%
Current ratio	3.25×	2.55×	1.6×	1.52×	1.49×
Debt / equity	0.05×	0.03×	0.8×	0.86×	0.64×
Interest coverage	3.91×	10.22×	7.16×	4.16×	19.72×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Return on equity	7.7%	11.1%	-0.6%	13.2%	-40.6%
Return on invested capital	5.6%	9.5%	-0.2%	5.1%	15.0%
Return on assets	4.7%	8.2%	-0.1%	2.9%	-8.2%
Free cash flow yield	13.7%	2.7%	1.6%	-1.2%	-1.8%
Earnings yield	3.6%	4.8%	-0.0%	0.8%	-2.0%
Enterprise value	₹69.1B	₹70.6B	₹119.3B	₹131B	₹128.7B
Net debt / EBITDA	-0.36×	-0.02×	3.48×	1.84×	-4.14×
Cash conversion cycle (days)	83	75	90	115	109